Adjuvant Pembrolizumab/Chemotherapy Misses DFS End Point in High-Risk Endometrial Cancer, but Benefits dMMR Subgroup - report from ESMO2024

from Medical Digest & Congress Report · host Medical Congress News

Professor Remi Nout shares his thoughts on the interim results of the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial that were presented during the ESMO Congress 2024. Video: https://medicaldigest.org/scientific-contents/interview:adjuvant-pembrolizumabchemotherapy-misses-dfs-end-point-high-risk-endometrial-cancer-benefits-dmmr-subgroup

Episode metadata supplied by the publisher feed · Published Sep 28, 2024

Embed this episode

Attribution link and audio player

Ready to play

Adjuvant Pembrolizumab/Chemotherapy Misses DFS End Point in High-Risk Endometrial Cancer, but Benefits dMMR Subgroup - report from ESMO2024

0:00 3:33

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 3 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on September 28, 2024.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!